Streptomyces avermitilis industrial strain as cell factory for Ivermectin B1a production

查看全文 作　　者：Qian [1]Deng;Liqiongzi [1]Xiao;Yang [1]Liu;Lixin [2]Zhang;Zixin [1]Deng;Changming [1]Zhao

机构地区：[1]Key Laboratory of Combinatorial Biosynthesis and Drug Discovery,Ministry of Education,School of Pharmaceutical Sciences,Wuhan University,Wuhan,China;[2]State Key Laboratory of Bioreactor Engineering,East China University of Science and Technology,Shanghai,China

出　　处：《Synthetic and Systems Biotechnology》索引2019年第4卷第1期,共6页

基　　金：the Ministry of Science and Technology of China(“973”Program 2013CB734003);the National Science Foundation of China(31670030). 摘　　要：Ivermectin,a kind of valuable derivatives of Avermectin,is distinct from Avermectin due to the saturated bond at C22eC23 position.Combinatorial biosynthesis of Ivermectins based on Avermectins biosynthetic gene cluster(ave)has been achieved recently,while the establishment of an Ivermectin homogeneous component producing strain is challenging because of the limited compatibility between the native and heterologous polyketide synthase(PKS)domains.In this study,the PKS module 2 Dehydratase(DH)-Enoylreductase(ER)-Ketoreductase(KR)domain set of Meilingmycin,which is another naturally occurring homologue of Avermectin,was employed to substitute the DH-KR domains of Avermectins PKS module 2 to generate an Ivermectin biosynthetic gene cluster(ive).Ivermectins B1a and A1a were heterologously biosynthesized in a classic actinomyces host Streptomyces lividans.The Avermectin B1a high-producing strain S.avermitilis 3-115 was genetically engineered to give an artificial host cell and Ivermectin B1a single component was effectively produced with a production of 1.25±0.14 g/L. 关键词：AVERMECTIN IVERMECTIN Meilingmycin Domain swapping Heterologo-us biosynthesis

相关文献

参考文献（26）
引证文献（3）
耦合文献（6）

参考文献(26)

引证文献(3)

耦合文献(6)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Streptomyces avermitilis industrial strain as cell factory for Ivermectin B1a production

参考文献(26)

引证文献(3)

耦合文献(6)

用户提示